[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623632":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":10,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Fujian Cancer Hospital","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Re-induction Chemotherapy Group",null,"This group consists of patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. These patients will receive re-induction chemotherapy followed by radiotherapy as part of their treatment regimen.",{"label":13,"type":10,"description":14,"interventionNames":10},"Direct Radiotherapy Group","This group consists of patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. These patients will receive direct radiotherapy without re-induction chemotherapy.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Yedong Huang, MD. PhD","CONTACT","+86 15959678182","drhuangyd@163.com",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Qiaojuan Guo","Director, Department of Head and Neck Radiation Oncology, Clinical Professor","100623632","crossroad-treatment-regimen-switch---re-induction-chemotherapy-vs-direct-radiotherapy-in-lanpc-with-inadequate-response-to-induction-chemotherapy-100623632",false,"NCT07399158","CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy","CROSSROAD: A Prospective Multicenter Observational Study on the Efficacy of Treatment Regimen Switch With Re-induction Chemotherapy Versus Direct Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma Patients With Inadequate Response (SD\u002FPD) After Induction Chemotherapy","Inclusion Criteria:\n\nAge: 18 to 70 years old.\n\nHistologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II\u002FIII).\n\nInitial treatment with no distant metastasis: Locally advanced nasopharyngeal carcinoma (according to the AJCC\u002FUICC 9th edition staging, stage II-III, i.e., T3-4N0-3M0 or T1-2N2-3M0).\n\nCompletion of two cycles of standard induction chemotherapy (such as TPF, GP, TP, etc.).\n\nPost-induction chemotherapy evaluation: Disease stability (SD) or disease progression (PD) after two cycles of induction chemotherapy, as assessed by RECIST 1.1 criteria, based on enhanced MRI of the nasopharynx.\n\nECOG Performance Status (PS): 0-1.\n\nBone marrow, liver, and kidney function: Sufficient to tolerate concurrent chemoradiotherapy (specific criteria to be referenced).\n\nInformed consent: Voluntary participation in the study and signing of written informed consent.\n\nExclusion Criteria:\n\nHistory of head and neck tumor radiotherapy or any other malignant cancer history (except for cured non-melanoma skin cancer).\n\nPartial response (PR) or complete response (CR) after induction chemotherapy.\n\nSevere uncontrolled comorbidities, such as unstable angina, congestive heart failure, severe chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes mellitus.\n\nActive infection or severe immunodeficiency diseases.\n\nPregnant or breastfeeding women.\n\nAny mental or social disorders that may interfere with study evaluation or compliance.\n\nOther conditions deemed by the investigator to be unsuitable for participation in the study.","ALL","18 Years","70 Years",{"count":36,"type":37},223,"ESTIMATED","OBSERVATIONAL","This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. The study will enroll patients who have completed two cycles of induction chemotherapy and have not achieved a partial or complete response. Participants will receive one of the two treatment options to evaluate their three-year progression-free survival (PFS) and other clinical outcomes.",[41],"Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2026-02-07",{"date":45,"type":46},"2026-02-10","ACTUAL",{"date":48,"type":37},"2026-02-01",{"date":50,"type":37},"2030-02-01",{"name":5,"class":6}]